Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16062848 | 0.69 | MLYCD (0.37) | — | |
| SCHEMBL25805741 | 0.67 | RXFP1 (0.34) | — | |
| SCHEMBL26897137 | 0.66 | MLYCD (0.30) | — | |
| SCHEMBL3060827 | 0.64 | ALDH1A1 (0.35) | — | |
| SCHEMBL12000463 | 0.63 | — | — | |
| SCHEMBL26858668 | 0.63 | MLYCD (0.33) | — | |
| SCHEMBL8254522 | 0.61 | LMNA (0.43) | — | |
| SCHEMBL13545654 | 0.60 | RXFP1 (0.33) | — | |
| SCHEMBL13222403 | 0.60 | PTGS1 (0.32) | — | |
| SCHEMBL12456225 | 0.60 | RXFP1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2592071-B1 | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2597089-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, TBXA2R | S1PR1 1/4885S1PR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.